[ad_1]
The agreement is non-proprietary and will allow the sharing of data – with the user's consent – between Abbott's FreeStyle Libre mobile application and Sanofi's cloud-connected insulin pens.
<p class = "canvas-atom-text-canvas Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The devices that will detect glucose and insulin levels, is the latest in a series of cooperative approaches undertaken by pharmaceutical companies in specialized markets.Abbott has already engaged with Bigfoot and Novo Nordisk (NOV), another major player in diabetes management. "data-reactid =" 33 "> This device, which will detect glucose levels and deliver insulin, is the latest in a series of cooperative approaches undertaken by pharmaceutical companies in markets Abbott is already engaged with Bigfoot and Novo Nordisk (NOV), another major player in diabetes management.
In a statement, Jared Watkin, senior vice president of diabetes care at Abbott, said the company expects "an important opportunity to impact the health of millions of people with diabetes." With the new tools.
Needle or insulin pen for the use of diabetics
"By partnering with Abbott, we are moving closer to realizing our connected ecosystem, which would help improve patient quality of life control and decision-making through individualized diabetes management," he said. Gustavo Pesquin, Executive Vice President of the Global Division of Diabetes. cardio franchise at Sanofi.
According to the Center for Disease Control, more than 30 million Americans live with diabetes today. The Abbott-Sanofi partnership is a new example of how smart devices are increasingly being used for health care – and to reduce costs.
The American Diabetes Association estimates that the cost of diabetes care exceeds $ 237 billion in 2017 and that an average of $ 16,475 is spent per person per year.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Meanwhile, the price of insulin The families reported & nbsp;rationing& nbsp; the doses needed for each refill to last last, which can have fatal consequences. "data-reactid =" 58 "> At the same time, the price of insulin has skyrocketed, with families reporting dose rationing so that each refill is sustainable., which can have fatal consequences.
It was not clear if the Abbott-Sanofi partnership could solve the problem of insulin rationing. However, Sanofi had previously stated that this would reduce the price of drugs for uninsured patients.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Anjalee Khemlani is a Yahoo Finance journalist. Follow her on Twitter: @AnjKhem"data-reactid =" 60 ">Anjalee Khemlani is a Yahoo Finance journalist. Follow her on Twitter: @AnjKhem
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Read the latest financial and commercial news from Yahoo Finance"data-reactid =" 61 ">Read the latest financial and commercial news from Yahoo Finance
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Follow Yahoo Finance onTwitter,Facebook,Instagram,Flipboard,SmartNews,LinkedIn, Youtube, and reddit."data-reactid =" 62 ">Follow Yahoo Finance onTwitter,Facebook,Instagram,Flipboard,SmartNews,LinkedIn, Youtube, and reddit.
[ad_2]
Source link